If Phylogica is the biotech, who is the academic making up the academic/biotech consortium referred to by Janssen in its presentation?
It may well be Cambridge University. If so, it would highlight the work of the spin-off company Phenomica re: application of Phylomers for target discovery and validation.
If Phylogica is the biotech, what is the target for the intracellular delivery of Centyrins? Joining some dots from other research, which may be extremely tenuous, the finger points towards cancer cells. Certainly within the Janssen presentation, Centyrins have been used to target tumor cells. What would appear to be more significant, however, is the wider role which Janssen appears to foreshadow for Centyrins.
Page 18 of the presentation - "develop Centyrins against undruggable intracellular therapeutic targets".
If I'm still on track with the analysis, then this would help explain why Paul Watts said in the 27 June 2013 announcement;
"This new technology [for developing peptide-drug conjugates targeting abnormal processes within cells] is game changing."
PYC Price at posting:
1.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)